Barclays analyst Luke Sergott maintained a Sell rating on Waters (WAT – Research Report) today and set a price target of $300.00. The company’s shares closed yesterday at $345.03.
According to TipRanks, Sergott is an analyst with an average return of -3.5% and a 41.50% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Catalent, Illumina, and Sotera Health.
Waters has an analyst consensus of Hold, with a price target consensus of $330.33.
Based on Waters’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $711.69 million and a net profit of $134.55 million. In comparison, last year the company earned a revenue of $708.56 million and had a net profit of $156 million
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WAT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Waters (WAT) Company Description:
Waters Corp. is a measurement company, which engages in the analytical workflow solutions involving liquid chromatography, mass spectrometry and thermal analysis innovations. It operates through Waters and TA segments. The Waters segment designs, manufactures, distributes and services liquid chromatography and ultra performance liquid chromatography instruments, columns and other chemistry consumables that can be integrated and used along with other analytical instruments. The TA Instruments segment designs, manufactures, distributes and services thermal analysis, rheometry and calorimetry instruments. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.
